JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function-Reference-Cited by-同舟云学术

JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function

Published:2020-02-12 Issue:530 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Adam Susanne¹²^ORCID,Simon Nils¹²^ORCID,Steffen Ulrike¹²^ORCID,Andes Fabian T.¹²,Scholtysek Carina¹²^ORCID,Müller Dorothea I. H.¹²,Weidner Daniela¹²,Andreev Darja¹²,Kleyer Arnd¹²^ORCID,Culemann Stephan¹²³,Hahn Madelaine¹²,Schett Georg¹²^ORCID,Krönke Gerhard¹²^ORCID,Frey Silke¹²^ORCID,Hueber Axel J.¹²^ORCID

Affiliation:

1. Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3–Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany.

2. Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany.

3. Nikolaus Fiebiger Center of Molecular Medicine, Universitätsklinikum Erlangen and Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Abstract

JAK inhibition enhances the function of bone-forming osteoblasts, increases bone mass, and induces repair of arthritic bone erosions.

Funder

Eli Lilly and Company

Pfizer

European Research Council

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

Innovative Medicines Initiative

Interdisciplinary Center for Clinical Research (IZKF) Universitätsklinikum Erlangen

Publisher

American Association for the Advancement of Science (AAAS)